With a revenue increase of 5.77% in the second quarter 2026, year on year to cumulative value of $1,037 million, Tandem Diabetes Care Inc 's revenue per employee grew on a trailing twelve months basis to $ 414,921. The productivity of Tandem Diabetes Care Inc 's employees was 0.0%, above the company average. Within the Healthcare sector Employees of 229 other companies have achieved higher revenue per employee. While Tandem Diabetes Care Inc 's total ranking has deteriorated compared to the previous quarter from 1282 to 1923. Tandem Diabetes Care Inc has 2,500 employees.
As we approach the closing months of 2025, Tandem Diabetes Care, Inc. (NASDAQ: TNDM) finds itself under not only the scrutiny of market analysts but also legal examination regarding its business practices. The Rosen Law Firm, a prominent global advocate for investor rights, has initiated inquiries into the company following allegations that it may have provided materially misleading information to shareholders. This revelation is particularly disconcerting in light of the company s recent financial performance, which, while notable in some respects, raises questions about the reliability of its disclosures.For the third quarter of 2025, Tandem Diabetes Care reported a revenue increase of 11.95% year-on-year, culminating in a remarkable cumulative revenue of $1,009 million setting a new company record. The firm’s revenue per employee also impressively grew to $420,336, a sign that productivity may be improving within its 2,400-strong workforce. In a sector where healthcare firms vigorously compete for investor confidence and market share, such numbers would typically be greeted with enthusiasm.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.
